MedTrace Logo

A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer

NCT05241613 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2025-02-13

No results posted yet for this study

Summary

This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies.

The main goals of this study are to:

* Identify the recommended dose of AC176 that can be given safely to participants
* Evaluate the side effects of AC176
* Evaluate pharmacokinetics of AC176
* Evaluate the effectiveness of AC176

Conditions

  • Metastatic Castration Resistant Prostate Cancer

Interventions

DRUG

AC176

AC176 will be given orally (PO) on a 28-day cycle.

Sponsors & Collaborators

  • Accutar Biotechnology Inc

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-16
Primary Completion
2024-03-05
Completion
2024-03-05
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05241613 on ClinicalTrials.gov